Form 4: Eledon Pharmaceuticals CEO Awarded Stock Options and Restricted Stock Units
SEC Form 4 Filing
Eledon Pharmaceuticals' CEO, David-Alexandre C. Gros, was granted stock options and restricted stock units as part of his compensation package.
Summary
- Eledon Pharmaceuticals' CEO, David-Alexandre C. Gros, received stock options for 600,000 shares at an exercise price of $4.04 per share.
- These options vest over a period starting January 10, 2026, with 150,000 shares vesting initially, followed by 6.25% of the remaining shares vesting quarterly until January 10, 2029.
- The CEO also received 66,500 restricted stock units (RSUs), each representing one share of common stock.
- These RSUs vest in two tranches: 50% on January 10, 2027, and the remaining 50% on January 10, 2028.
- Both the stock options and RSUs are subject to accelerated vesting under certain conditions, such as termination of employment or a change of control of the company.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which are generally viewed positively as they align management's interests with shareholders. There are no negative implications.
Positives
- The grant of stock options and RSUs aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
- The accelerated vesting provisions provide protection for the CEO in the event of certain terminations or a change of control.
Risks
- The value of the stock options and RSUs is dependent on the future performance of the company's stock price.
- The vesting of the options and RSUs is contingent on the CEO's continued employment with the company.
Future Outlook
The document does not contain any specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.
Industry Context
The granting of stock options and restricted stock units is a common practice in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option and RSU grants are standard practice for executive compensation in the biotech and pharmaceutical industries.
- Vesting schedules are typically structured to align with long-term company performance and executive retention.
- The specific terms of the grants, such as the exercise price and vesting periods, are often tailored to the individual company and executive.
Stakeholder Impact
- Shareholders may view the grants positively as they incentivize the CEO to increase the company's value.
- Employees may see the grants as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of the stock option and RSU grants. |
| 01/10/2026 | First vesting date for 150,000 of the stock options. |
| 01/10/2027 | First vesting date for 50% of the restricted stock units. |
| 01/10/2028 | Second vesting date for the remaining 50% of the restricted stock units. |
| 01/10/2029 | Final vesting date for the stock options. |
| 01/10/2035 | Expiration date of the stock options. |
| 01/13/2025 | Date the form was signed. |
Keywords
stock options, restricted stock units, executive compensation, vesting, Eledon Pharmaceuticals, David-Alexandre C. Gros, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.